Literature DB >> 30296444

Plasma metabolomic profiling distinguishes right-sided from left-sided colon cancer.

Kui Deng1, Peng Han2, Wei Song1, Zhuozhong Wang1, Fan Zhang1, Hongyu Xie1, Weiwei Zhao1, Huan Xu1, Yuqing Cai1, Zhiwei Rong1, Xiwen Yu3, Bin-Bin Cui4, Kang Li5.   

Abstract

BACKGROUND: Many studies have demonstrated that right-sided colon cancer (RCC) has a higher mortality rate and worse prognosis than left-sided colon cancer (LCC). However, the underlying biological mechanism that can account for these differences is unclear.
METHODS: In this study, plasma metabolic profiles in 147 LCC patients and 105 RCC patients were systematically analyzed by the ultra high performance liquid chromatography quadruple time-of-flight mass spectrometry (UHPLC-QTOF/MS) platform in conjunction with univariate and multivariate statistical analysis.
RESULTS: Metabolic signatures revealed considerable differences between patients with RCC and LCC, and clear separations were observed between the two groups in partial least-squares discriminant analysis score plots. In total, six metabolites were identified as potential metabolite markers for tumor location in RCC compared with LCC, including upregulated trimethylamine N-oxide and indoxyl sulfate, and downregulated anserine, L-targinine, gamma-glutamyl-gamma-aminobutyraldehyde and pyridoxal 5'-phosphate. These differences highlight that significant alternations occur in the pathways of methane metabolism, arginine and proline metabolism, histidine metabolism, beta-alanine metabolism and vitamin B6 metabolism in RCC compared with LCC.
CONCLUSIONS: Identified biomarkers and metabolic pathways may facilate our understanding of the different mortality rates and prognoses between RCC and LCC.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Colorectal cancer; Left-sided colon cancer; Metabolomics; Plasma; Right-sided colon cancer; Tumor location

Mesh:

Substances:

Year:  2018        PMID: 30296444     DOI: 10.1016/j.cca.2018.10.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  The Role of Liquid Biopsy Analytes in Diagnosis, Treatment and Prognosis of Colorectal Cancer.

Authors:  JinHua He; NaiTe Xi; ZePing Han; WenFeng Luo; Jian Shen; ShengBo Wang; JianHao Li; ZhongHui Guo; HanWei Cheng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

2.  Lipid profiling suggests species specificity and minimal seasonal variation in Pacific Green and Hawksbill Turtle plasma.

Authors:  Chelsea E Clyde-Brockway; Christina R Ferreira; Elizabeth A Flaherty; Frank V Paladino
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

3.  N-glycomic profiling of colorectal cancer according to tumor stage and location.

Authors:  Matilda Holm; Pirjo Nummela; Annamari Heiskanen; Tero Satomaa; Tuomas Kaprio; Harri Mustonen; Ari Ristimäki; Caj Haglund
Journal:  PLoS One       Date:  2020-06-29       Impact factor: 3.240

4.  Plasma protein expression differs between colorectal cancer patients depending on primary tumor location.

Authors:  Matilda Holm; Sakari Joenväärä; Mayank Saraswat; Tiialotta Tohmola; Ari Ristimäki; Risto Renkonen; Caj Haglund
Journal:  Cancer Med       Date:  2020-05-26       Impact factor: 4.452

5.  Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts.

Authors:  Daniela D Weber; Maheshwor Thapa; Sepideh Aminzadeh-Gohari; Anna-Sophia Redtenbacher; Luca Catalano; René G Feichtinger; Peter Koelblinger; Guido Dallmann; Michael Emberger; Barbara Kofler; Roland Lang
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

6.  Salivary metabolomics with machine learning for colorectal cancer detection.

Authors:  Hiroshi Kuwabara; Kenji Katsumata; Atsuhiro Iwabuchi; Ryutaro Udo; Tomoya Tago; Kenta Kasahara; Junichi Mazaki; Masanobu Enomoto; Tetsuo Ishizaki; Ryoko Soya; Miku Kaneko; Sana Ota; Ayame Enomoto; Tomoyoshi Soga; Masaru Tomita; Makoto Sunamura; Akihiko Tsuchida; Masahiro Sugimoto; Yuichi Nagakawa
Journal:  Cancer Sci       Date:  2022-07-08       Impact factor: 6.518

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.